The detection of anti-erythropoietin antibodies in human serum and plasma Part II.: Validation of a semi-quantitative 3H-thymidine uptake assay for neutralizing antibodies

被引:18
作者
Kelley, M
Cooper, C
Matticoli, A
Greway, A
机构
[1] Centocor Inc, Radnor, PA 19087 USA
[2] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
anemia; erythropoietin; neutralizing anti-erythropoietin antibodies; cytokines; radioimmunoprecipitation; stem cell factor; thymidine uptake; UT-7/EPO; bioassay;
D O I
10.1016/j.jim.2005.03.013
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Neutralizing antibodies to erythropoietin (EPO) can cause a loss of response to recombinant human EPO (rHuEPO) and lead to rare cases of sudden, unexplained, severe anemia in chronic renal failure patients treated with rHuEPO. An assay for neutralizing anti-EPO antibodies has been validated that is based on the inhibition of proliferation of human UT-7/EPO cells, an immortalized cell line, by neutralizing antibodies in serum test samples using H-3-thymidine as a marker for proliferation. The dependence of the human cell line on EPO for growth and proliferation in a concentration-dependent manner enabled the validation of a rHuEPO standard curve for cell proliferation that can be used to determine the presence of neutralizing anti-EPO antibodies in serum samples. Proliferation of the cells increases with increasing concentrations of EPO, forming an S-shaped standard curve, which is fit with a 4-parameter logistic model, between 2.5 and 50 mU/mL rHuEPO, with a percent coefficient of variation (% CV) from 8.7% to 22.1% and a % accuracy of 103.5% to 109.5%. Anti-EPO antibodies and serum with anti-EPO antibodies neutralize UT-7/EPO proliferation by 10 mU/mL rHuEPO in a concentration- or dilution-dependent manner with <= 25% CV. Percent neutralization is calculated by determining the amount of EPO recovered from the original 10 mU/mL added using the formula [((10 -concentration recovered)/ 10) x 100%]. Stem cell factor (SCF) stimulated cell proliferation, but not as effectively as rHuEPO. Antibodies to SCF were not able to inhibit the proliferative response induced by EPO and vice versa, confirming the specificity of the assay for antibodies to EPO. High EPO levels can impact both the radiomirminoprecipitation and neutralization assays to produce a false negative result. However, the impact can be mitigated by the large dilutions used in the neutralization assay. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:179 / 191
页数:13
相关论文
共 30 条
[1]
Prognostic and predictive value of thymidine labelling index in breast cancer [J].
Amadori, D ;
Silvestrini, R .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (03) :267-281
[2]
Effects of growth hormone and estrogen on T lymphocytes in older women [J].
Bonello, RS ;
Marcus, R ;
Bloch, D ;
Strober, S .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1996, 44 (09) :1038-1042
[3]
Drug-induced autoimmune red-cell aplasia. [J].
Bunn, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :522-523
[4]
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].
Casadevall, N ;
Nataf, J ;
Viron, B ;
Kolta, A ;
Kiladjian, J ;
Martin-Dupont, P ;
Michaud, P ;
Papo, T ;
Ugo, V ;
Teyssandier, I ;
Varet, B ;
Mayeux, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475
[5]
Antibodies against rHuEPO: native and recombinant [J].
Casadevall, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :42-47
[6]
Brief report: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia [J].
Casadevall, N ;
Dupuy, E ;
MolhoSabatier, P ;
Tobelem, G ;
Varet, B ;
Mayeux, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (10) :630-633
[7]
Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients [J].
Cascinu, S ;
DelFerro, E ;
Grianti, C ;
Ligi, M ;
Ghiselli, R ;
Foglietti, G ;
Saba, V ;
Lungarotti, F ;
Catalano, G .
GASTROENTEROLOGY, 1997, 113 (03) :767-772
[8]
Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin [J].
Castelli, G ;
Famularo, A ;
Semino, C ;
Machi, AM ;
Ceci, A ;
Cannella, G ;
Melioli, G .
PHARMACOLOGICAL RESEARCH, 2000, 41 (03) :313-318
[9]
Dorai H, 2001, J BONE JOINT SURG AM, V83A, pS70
[10]
CHARACTERIZATION AND BIOLOGICAL EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
EGRIE, JC ;
STRICKLAND, TW ;
LANE, J ;
AOKI, K ;
COHEN, AM ;
SMALLING, R ;
TRAIL, G ;
LIN, FK ;
BROWNE, JK ;
HINES, DK .
IMMUNOBIOLOGY, 1986, 172 (3-5) :213-224